This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
by Zacks Equity Research
Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.
SNYPositive Net Change NVAXPositive Net Change CRMDNegative Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
BAYRYNegative Net Change CRMDNegative Net Change VTRSPositive Net Change IMCRPositive Net Change
earnings medical pharmaceuticals
Jobless Claims, Q2 Productivity, Q2 Earnings All Higher
by Mark Vickery
Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
LLYPositive Net Change GILDNegative Net Change WYNNNegative Net Change TTWOPositive Net Change RLPositive Net Change WBDNegative Net Change TRIPNegative Net Change TWLONegative Net Change
apparel consumer-discretionary earnings pharmaceuticals staffing
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
CPRXNegative Net Change CRMDNegative Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
CRMDNegative Net Change ACADNegative Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
by Zacks Equity Research
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
RHHBYPositive Net Change SRPTNegative Net Change ARWRPositive Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
by Zacks Equity Research
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
CRMDNegative Net Change ADMANegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
by Zacks Equity Research
NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.
NVONegative Net Change LLYPositive Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
CRMDNegative Net Change ARVNPositive Net Change IMCRPositive Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
REGNNegative Net Change RAREPositive Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View
by Zacks Equity Research
BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and Xarelto headwinds.
REGNNegative Net Change JNJPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
by Zacks Equity Research
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.
AZNPositive Net Change NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change
pharmaceuticals
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Ekta Bagri
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
ZTSNegative Net Change CRMDNegative Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth
by Zacks Equity Research
PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.
BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
pharmaceuticals
Trade Deficit Narrowed More Than Expected
by Zacks Equity Research
Trade Deficit Narrowed More Than Expected
AMDNegative Net Change BPNo Net Change CATNegative Net Change PFEPositive Net Change AMGNNegative Net Change SWKSNegative Net Change MPCPositive Net Change GLDDNegative Net Change ANETNegative Net Change MTCHNegative Net Change TRVGNegative Net Change SNAPPositive Net Change
computers construction medical oil-energy pharmaceuticals tech-stocks utilities
Pre-markets Slightly Up on Mostly Good Q2 Earnings
by Mark Vickery
Q2 earnings reports are overall posting favorable results, including this morning ahead of the open.
AMDNegative Net Change BPNo Net Change CATNegative Net Change PFEPositive Net Change AMGNNegative Net Change SWKSNegative Net Change MPCPositive Net Change GLDDNegative Net Change ANETNegative Net Change MTCHNegative Net Change TRVGNegative Net Change SNAPPositive Net Change
earnings pharmaceuticals tech-stocks
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
by Zacks Equity Research
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
SNYPositive Net Change BMRNPositive Net Change GMABPositive Net Change IMCRPositive Net Change
biotechs earnings medical pharmaceuticals
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
CPRXNegative Net Change ACADNegative Net Change DNLIPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
by Ekta Bagri
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
by Zacks Equity Research
Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.
BAYRYNegative Net Change CRMDNegative Net Change KRYSPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
PFEPositive Net Change EXASPositive Net Change AMRXPositive Net Change VTRSPositive Net Change
biotechnology medical pharmaceuticals
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
ZTSNegative Net Change ACADNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change GILDNegative Net Change
biotechs pharmaceuticals